ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $107.33 Consensus PT from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been assigned a consensus rating of “Moderate Buy” from the eight research firms that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $107.3333.

Several research firms recently issued reports on ANIP. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Zacks Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 15th. Guggenheim upped their price target on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Finally, Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 14th.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Thomas Andrew Rowland sold 4,772 shares of the company’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total transaction of $357,470.52. Following the sale, the senior vice president owned 38,730 shares in the company, valued at $2,901,264.30. This represents a 10.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Stephen P. Carey sold 7,312 shares of the company’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $75.50, for a total value of $552,056.00. Following the sale, the chief financial officer owned 185,543 shares in the company, valued at approximately $14,008,496.50. This trade represents a 3.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 27,860 shares of company stock worth $2,111,581 over the last quarter. 11.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several large investors have recently bought and sold shares of ANIP. Vanguard Group Inc. increased its holdings in shares of ANI Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after acquiring an additional 27,598 shares during the last quarter. State Street Corp increased its holdings in shares of ANI Pharmaceuticals by 2.2% in the 4th quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock valued at $57,405,000 after acquiring an additional 15,496 shares during the last quarter. UBS Group AG increased its holdings in shares of ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after acquiring an additional 185,172 shares during the last quarter. Tang Capital Management LLC increased its holdings in shares of ANI Pharmaceuticals by 51.6% in the 4th quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company’s stock valued at $38,005,000 after acquiring an additional 163,937 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of ANI Pharmaceuticals by 4.2% in the 4th quarter. Geode Capital Management LLC now owns 477,272 shares of the specialty pharmaceutical company’s stock valued at $37,682,000 after acquiring an additional 19,258 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Price Performance

ANIP opened at $80.14 on Thursday. The stock’s 50-day moving average price is $76.24 and its 200 day moving average price is $81.74. ANI Pharmaceuticals has a 12-month low of $56.71 and a 12-month high of $99.50. The company has a current ratio of 2.71, a quick ratio of 2.19 and a debt-to-equity ratio of 1.11. The firm has a market cap of $1.80 billion, a price-to-earnings ratio of 23.85 and a beta of 0.44.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.